Hims & Hers Health
HIMS NYSE· Health Care Services
Last close · Oct 27, 2026
$27.92
KIRA · Stoqly’s AI analyst, in plain words
- Hims & Hers Health had $2.3B of revenue in fiscal 2025, up 59.0% on the year before. Over five years, revenue changed +73.6% a year on average.
- Its operating margin was 4.5%, up 0.3 pts: of every 100 in sales, about 5 is left after running the business.
- Hims & Hers Health made $128M of net profit in fiscal 2025.
- Free cash flow was $57.4M in fiscal 2025, 2.5% of revenue.
- Hims & Hers Health returned $90.0M to shareholders in fiscal 2025, 157% of free cash flow. The diluted share count rose 9.1%.
- Hims & Hers Health owes $395M more than it holds in cash, about 2.5 years of operating profit.
Market cap
$6.5B
P/E
—
Revenue
$2.3B
Net income
$128M
Free cash flow
$57.4M
Operating margin
4.5%
Hims & Hers Health in 30 seconds · fiscal 2025
Are sales growing?
+59.0%
Yes. Sales grew 59.0% last year.
Does it make a profit?
5.5%
A little. It keeps 5.5% of every sale as profit.
Does profit turn into cash?
2.5%
Partly. 2.5% of sales ends up as free cash.
Is debt under control?
2.5x
Keep an eye on it. Repaying its debt would take 2.5 years of operating profit.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
What Hims & Hers Health does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 23, 2026
- Legal name
- HIMS & HERS HEALTH, INC.
- CIK
- 0001773751
Hims & Hers Health · HIMS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $272M | $527M | $872M | $1.5B | $2.3B |
| Revenue growth | 82.8% | 93.8% | 65.5% | 69.3% | 59.0% |
| Gross margin | 75.2% | 77.6% | 82.0% | 79.5% | 73.8% |
| Operating margin | −42.3% | −13.0% | −3.4% | 4.2% | 4.5% |
| Net income | −$108M | −$65.7M | −$23.5M | $126M | $128M |
| Net margin | −39.6% | −12.5% | −2.7% | 8.5% | 5.5% |
| Diluted EPS | −$0.58 | −$0.32 | −$0.11 | $0.53 | $0.51 |
| Cash | |||||
| Cash from operations | −$34.4M | −$26.5M | $73.5M | $251M | $300M |
| Capital expenditure | $0.8M | $7.2M | $26.5M | $52.8M | $243M |
| Free cash flow | −$35.2M | −$33.7M | $47.0M | $198M | $57.4M |
| FCF margin | −13.0% | −6.4% | 5.4% | 13.4% | 2.5% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $0.0M | $0.0M | $2.0M | $83.0M | $90.0M |
| Share count change | 428.3% | 9.5% | 2.4% | 13.1% | 9.1% |
| Debt and strength | |||||
| Cash and short-term investments | $247M | $180M | $221M | $300M | $578M |
| Debt incl. finance leases | $0.0M | $0.0M | $0.0M | $0.0M | $973M |
| Shareholders' equity | $335M | $312M | $344M | $477M | $541M |
| Net debt / EBITDA | — | — | — | −3.8x | 2.5x |
| Current ratio | 3.4x | 4.5x | 3.0x | 1.8x | 1.9x |
| Returns and quality | |||||
| Return on capital | — | −49.5% | −18.2% | 41.3% | 19.0% |
| Return on equity | −114.7% | −20.3% | −7.2% | 30.7% | 25.2% |
| Piotroski F-score | 3 | 4 | 5 | 5 | 4 |
| Altman Z'' | 3.1 | 4.7 | 3.2 | 3.3 | 1.6 |
Insiders bought, 12 months
$1.2M
1 insider
Insiders sold, 12 months
$19.3M
8 insiders
Of sales under plans
99%
$19.2M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Hims & Hers Health · HIMS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Hims & Hers Health HIMS | $6.5B | 59.0% | 4.5% | 2.5% | 19.0% | — | 4 |
| Chemed CHE | $6.7B | 4.1% | 13.4% | 12.9% | 27.3% | 25.6x | 5 |
| Concentra Group Holdings Par... CON | $5.1B | 13.9% | 15.4% | 9.1% | 14.9% | 25.8x | 5 |
| Amn Healthcare Services AMN | $1.9B | −8.5% | −2.0% | 8.6% | −2.8% | 17.4x | 5 |
| Lifestance Health LFST | $5.1B | 13.9% | 1.7% | 7.7% | 1.2% | 100.8x | 7 |
KIRA
At $27.92 a share, the company is worth $6.5B.
Hims & Hers Health grew sales faster than 4 of its 4 similar companies.
Source: SEC EDGAR XBRL filings (CIK 0001773751). Data updated October 11, 2026. For information only — not investment advice. Check the original filings before relying on any figure.